← Back
Data updated: Mar 10, 2026
HARROW EYE
OphthalmologyInfectious DiseaseDermatology
HARROW EYE is a major pharmaceutical company focused on Ophthalmology, Infectious Disease, Dermatology. Key products include ILEVRO.
1962
Since
19
Drugs
-
Trials
6
Approved (2yr)
Key Drugs
ILEVRO
nepafenac
Prostaglandin H synthase 2 indications · 2012
BYQLOVI
clobetasol propionate
Phospholipase A2 2 indications · 2024
IHEEZO
chloroprocaine hydrochloride
1 indications · 2022
VERKAZIA
cyclosporine
1 indications · 2021
ZERVIATE
cetirizine hydrochloride
H1 receptor 1 indications · 2017
Recent Activity
NATACYN 2025-11-17
Labeling
FLAREX 2025-09-23
Labeling
VEVYE 2025-09-18
Labeling
BYQLOVI 2025-04-07
Labeling
VEVYE 2024-05-28
Labeling
FLAREX 2024-05-24
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 50%
5 drugs
Infectious Disease 40%
4 drugs
Dermatology 10%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Infectious Disease, Dermatology, Ophthalmology
B BRAUN specialty
Infectious Disease, Ophthalmology, Dermatology
BAUSCH AND LOMB specialty
Ophthalmology, Infectious Disease, Dermatology
FOUGERA PHARMS other
Dermatology, Ophthalmology, Infectious Disease
Pfizer big-pharma
Infectious Disease, Dermatology